The European Commission has inked the pre-purchase agreement over Valneva’s inactivated whole virus pandemic vaccine VLA2001 announed in mid-October.
Swiss Vifor Pharma is shelling out more than €375m for Mallorca-based Sanifit, a clinical-stage cardio-renal biopharmaceutical company with a single compound in development.
Novo Nordisk announced today that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals for up to US$ 3.3bn, which is a surcharge of about 80%.
Pfizer Inc announced it will allow generic makers in 95 low income nations to produce and distribute its COVID-19 pill Paxlovid at cost price.
London-based Synthace, which develops software to automate biology experimentation, has raised US$35m in a Series C from notable investors.
The EU has secured 60 million doses of Valneva’s potential Covid-19 vaccine VLA2001. When approvied, it would be the first inactivated vaccine on the EU market.
Life Sciences investor LSP is set to being acquired by Europe’s largest equity specialist EQT AB.
Two European oncology biopharma companies have made the leap onto the stock market: French MaaT Pharma went public on Euronext Paris, while Danish IO Biotech chose Nasdaq Global Market for its IPO.
European life science investor LSP has raised €850m for its 7th generation flagship fund LSP 7.
Dunad Therapeutics Ltd had entered into a $1.3bn option deal with Swiss pharma major Novartis AG to develop targeted protein degrader therapies.